Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory ... Read More
Eli Lilly to acquire Morphic in $3.2bn deal to expand integrin therapy development
In a major strategic move, Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical ... Read More